EF
REGN icon

Empirical Finance’s Regeneron Pharmaceuticals REGN Stock Holding History

Empirical Finance’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.16M Sell
1,501
-15
-1% -$11.5K 0.05% 273
2025
Q4 		$1.17M Sell
1,516
-410
-21% -$278K 0.06% 264
2025
Q3 		$1.08M Sell
1,926
-1
-0.1% -$565 0.05% 292
2025
Q2 		$1.01M Buy
1,927
+298
+18% +$166K 0.05% 292
2025
Q1 		$1.03M Sell
1,629
-2
-0.1% -$1.38K 0.06% 267
2024
Q4 		$1.16M Sell
1,631
-48
-3% -$40.3K 0.07% 241
2024
Q3 		$1.77M Sell
1,679
-61
-4% -$67.9K 0.1% 173
2024
Q2 		$1.83M Sell
1,740
-236
-12% -$229K 0.11% 159
2024
Q1 		$1.9M Sell
1,976
-12
-0.6% -$11.4K 0.12% 163
2023
Q4 		$1.75M Sell
1,988
-2
-0.1% -$1.65K 0.12% 159
2023
Q3 		$1.64M Sell
1,990
-1
-0.1% -$786 0.12% 153
2023
Q2 		$1.43M Sell
1,991
-673
-25% -$519K 0.11% 166
2023
Q1 		$2.19M Buy
2,664
+106
+4% +$79.9K 0.21% 104
2022
Q4 		$1.85M Buy
2,558
+240
+10% +$177K 0.19% 111
2022
Q3 		$1.6M Buy
2,318
+441
+23% +$278K 0.19% 112
2022
Q2 		$1.11M Buy
1,877
+776
+70% +$504K 0.14% 139
2022
Q1 		$769K Buy
1,101
+220
+25% +$139K 0.09% 220
2021
Q4 		$556K Buy
881
+509
+137% +$313K 0.07% 275
2021
Q3 		$225K Buy
+372
New +$231K 0.03% 396
2017
Q1 		– Sell
-44
Closed -$17K – 467
2016
Q4 		$17K Buy
+44
New +$16.7K 0.01% 224

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Empirical Finance's REGN Position: Q1 2026 in Review

Empirical Finance reduced its Regeneron Pharmaceuticals (REGN) stake by 0.99% in Q1 2026, selling an estimated $11.5K and leaving 1,501 shares worth $1.16M. The position accounts for 0.05% of the portfolio, ranked #273.

Empirical Finance first reported a position in REGN in Q4 2016 and has held it in 20 quarters since. The position peaked at $2.19M in Q1 2023. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Empirical Finance held 1,501 shares of Regeneron Pharmaceuticals worth $1.16M as of Q1 2026.
  • Empirical Finance sold 15 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $11.5K.
  • Regeneron Pharmaceuticals made up 0.05% of Empirical Finance's portfolio in Q1 2026, its #273 holding.
  • Empirical Finance first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 20 quarters since.
  • Empirical Finance's Regeneron Pharmaceuticals position peaked at $2.19M in Q1 2023.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Empirical Finance's 13F filing for Q1 2026, filed 14 May 2026.